Table 2.
Results of human magnetic luminex assay
| Assay | CFVR < 2 (n = 6) | CFVR ≥ 2 (n = 15) | p value |
|---|---|---|---|
| Angiopoetin-2 (pg/ml) | 3274 (1000–5136) | 3051 (2230–4053) | 0.850 |
| Atrial natriuretic peptide (pg/ml) | 25,836 ± 9520 | 20,568 ± 11,210 | 0.329 |
| Detectable KIM-1 n (%) | 2 (33) | 5 (31) | 1.0 |
| Galectin-3 (ng/ml) | 1.3 (1-1.3) | 1.3 (1-1.4) | 0.791 |
| IL-1ra (pg/ml) | 667 (526–742) | 515 (384–729) | 0.850 |
| IL-6 (pg/ml) | 2.09 ± 1.3 | 2.69 ± 1.35 | 0.371 |
| IL-8 (pg/ml) | 6.1 (4.2–11.5) | 11.4 (8–23) | 0.132 |
| IL-10 (pg/ml) | 2.5 (0.9–4.1) | 1.4 (0.9–3.4) | 1.0 |
| Leptin (ng/ml) | 17.7 (6.6–20.6) | 13.2 (4.2–50.4) | 0.910 |
| MCP-1 (pg/ml) | 396 ± 221 | 375 ± 102 | 0.770 |
| MMP-9 (pg/ml) | 10,614 (4955–11,509) | 9880 (6244–13,648) | 1.0 |
| NGAL (ng/ml) | 26.3 ± 8.9 | 26.6 ± 4.8 | 0.898 |
| ST2 (ng/ml) | 14 (10–33) | 12 (9–19) | 0.850 |
| TNF (pg/ml) | 6.1 (4.5–8.1) | 5.7 (5.1–6.7) | 0.850 |
| Uromodulin (ng/ml) | 18 ± 9 | 21 ± 10 | 0.53 |
| VEGF (pg/ml) | 52 ± 26 | 75 ± 25 | 0.108 |
Data are presented as mean ± SD or median (IQR)
CFVR, coronary flow velocity reserve; KIM-1, kidney injury molecule 1; IL-1ra, interleukin 1 receptor antagonist; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; MCP-1, monocyte chemoattractant protein; MMP-9, matrix metallopeptidase 9; NGAL, neutrophil gelatinase associated lipocalin; ST2, suppression of tumorigenicity 2; TNFα, tumour necrosis factor alpha; VEGF, vascular endothelial growth factor.